

# SECTION 29 ACCESS TO MPOX PREVENTATIVE ADVICE – FROM 1 SEPTEMBER 2023

## INITIAL ENGAGEMENT

1

Consumer engages with a **health provider**

2

**Informed conversation** with **Medical Practitioner\*** (MP) if able to facilitate end to end process (see step 4), or refer to known provider

3

MP issues **Prescription** to consumer for Section 29 medicine and **appointment** made for administration

## PLANNING & ORDERING

4

(A. or B.)

**A. Existing Sites** have established access as part of the initial mpox Programme

**B. New Sites** who wish to get set up to manage mpox vaccinations on-site

5

Submit **HCL CS012 Section 29 Supply form**

## FOLLOW UP & ADMINISTRATION

6

HCL advise Te Whatu Ora to raise order, HCL **fulfils order**

7

Consumer returns for **Vaccination**



**A. EXISTING SITE** Follow up can be scheduled immediately or upon stock order



I.e.



Primary Care Site



Sexual Health Clinic



Travel Doctors Site

The **mpox Vaccine Prescriber Guide** is available directly and via Health Pathways

Te Whatu Ora funds the medicine and supply chain cost

### B. NEW SITE



Allow two to four weeks to complete on-boarding actions



Review **mpox Toolkit**



If not already using **CIR or Inventory Portal**, register site for distribution



Vaccinator completes **IMAC Training Webinar**

2 vials will be distributed for each prescription.

Distribution will be to the address listed in CIR/Inventory Portal, but **can be safely transported as outreach** following cold chain protocols

If required, Site can **recall consumer** on stock confirmation



Doses recorded on **PMS** and stored by the site



**Written Consent** is archived by the site



HCL stores patient information to **report to Medsafe**

\*A **medical practitioner** is a health practitioner registered with the Medical Council of New Zealand as a practitioner of the profession of medicine.

**Medical practitioners** can prescribe **unapproved** medicines that have been manufactured in New Zealand or imported into New Zealand under section 29 of the *Medicines Act 1981*.

The mpox Vaccination is a **two dose course** with **28 days spacing** between doses.

There is a **28 day standdown** following **COVID-19 vaccination** / end of **COVID-19 infection**